Nvidia Shares Dropped After Stellar Earnings: Outlook
Nvidia stunned the market with strong earnings, yet the stock fell. This article explains why the drop happened, what...
Articles — Page 1070
Xometry's (XMTR) Recently Sold: What Investors Should Do
When a CEO optimizes liquidity by selling shares, it sparks questions. This guide dives into xometry's (xmtr) recentl...
Three Things Long-Term Investors Should Do as June Arrives
June is a perfect time to reset for long-term investing. Here are three practical steps that align your portfolio wit...
Interested Humanoid Robot Stocks? Try This Robotics ETF
The humanoid robot boom is reshaping how we think about investing in AI and automation. This guide explains why a rob...
Top Cryptocurrency Before Soars 1,600%: Ark Invest Insight
Cathie Wood of Ark Invest has sparked big talk about where crypto could go. This article outlines a practical approac...
UK Treats Crypto Network Like Banks After Russia Sanctions
London expands sanctions by applying bank-style rules to crypto exchanges and targeting the Kremlin-backed A7 network...
Kalvista's (Kalv) Chief Development Insider Trade Watch
When a top executive sells shares after exercising options, markets take note. This deep dive breaks down Kalvista's ...
Better Inference Stock Own: Nvidia vs Cerebras Face-Off
In the race to dominate AI inference, two hardware contenders stand out: Nvidia and Cerebras. This guide breaks down ...
Marvell Technology Stock After Strong Outlook: Buy or Hold?
Marvell Technology surprised the market with a stronger revenue outlook. This in-depth guide examines what that means...
Buckle Nasdaq Index Fund: SpaceX Could Become a Holding
SpaceX going public could redefine the balance of big-name holdings in passive portfolios. This guide explains what b...
Billionaires Just Sold Shares of AI Giant: What It Means
Quarterly filings reveal big-money moves. Seven of eight ultra-rich fund managers trimmed a single AI stock that’s su...
Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...